SCHEMBL4358781

SCHEMBL4358781

Cc1ccc(C=C2SC(N3CCN(c4ncccc4Cl)CC3)=NC2=O)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.65
RAB9A P51151 2/20 0.64
ENPP2 Q13822 2/20 0.55
HTT P42858 1/20 0.53
ALDH1A1 P00352 3/20 0.52
MEN1 O00255 5/20 0.52
KMT2A Q03164 5/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HSD11B1 P28845 1/20 0.51
DCTPP1 Q9H773 1/20 0.51
ALOX5 P09917 2/20 0.50
MAPK1 P28482 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GRIN1 Q05586 2/20 0.49
GRIN2B Q13224 2/20 0.49
NPC1 O15118 2/20 0.49
IDE P14735 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4358777 1.00 MAPT (0.65) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4364677 0.90 ALDH1A1 (0.65) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4364671 0.90 ALDH1A1 (0.65) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4352362 0.90 HTT (0.68) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4352360 0.90 HTT (0.68) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4354015 0.90 ENPP2 (0.53) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4354018 0.90 ENPP2 (0.53) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4356144 0.87 ALDH1A1 (0.53) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4356142 0.87 ALDH1A1 (0.53) MAPTRAB9AENPP2HTTALDH1A1
SCHEMBL4363216 0.85 ENPP2 (0.55) MAPTENPP2HTTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885RAB9A 3151/4885ENPP2 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.